Spotlight on Family Medicine

Credits: 1.00 CME / CNE / CPE
Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions
J. Mark FitzGerald, MB, MD, FRCPC
Integrity Continuing Education, Inc.

Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 25, 2020
Expires: June 25, 2021
1 hour to complete

Accredited By

This CME activity for ACCME credit is provided by Integrity Continuing Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

Target Audience

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids

Activity Description

This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

Statement of Educational Need

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.

Faculty

J. Mark FitzGerald, MB, MD, FRCPC (Faculty Presenter)
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Designation of Credit

Physician Credit
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 25, 2020
Expires: June 25, 2021
1 hour to complete

Accredited By

This CME activity for ACCME credit is provided by Integrity Continuing Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

Target Audience

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids

Activity Description

This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

Statement of Educational Need

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.

Faculty

J. Mark FitzGerald, MB, MD, FRCPC (Faculty Presenter)
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Designation of Credit

Physician Credit
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Family Medicine Presentations

0.25 CME
Vindico
Immune-Mediated Inflammatory Disease Curbside Consults: RA – What to Do After TNF Failure?

Immune-Mediated Inflammatory Disease Curbside Consults: RA – What to Do After TNF Failure?

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to review the latest clinical evidence regarding tumor necrosis factor inhibitor (TNFi) cycling versus switching strategies after first-line TNFi failure.

Activity Description

In this Curbside Consult video, Drs. Leonard Calabrese and Stanley Cohen discuss strategies for managing RA in a patient after loss of response to first-line TNF inhibitor therapy.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Stanley B. Cohen, MD
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, TX

Disclosures:
Consulting Fee: AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Contracted Research(Paid to Institution): AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to review the latest clinical evidence regarding tumor necrosis factor inhibitor (TNFi) cycling versus switching strategies after first-line TNFi failure.

Activity Description

In this Curbside Consult video, Drs. Leonard Calabrese and Stanley Cohen discuss strategies for managing RA in a patient after loss of response to first-line TNF inhibitor therapy.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Stanley B. Cohen, MD
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, TX

Disclosures:
Consulting Fee: AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Contracted Research(Paid to Institution): AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

0.50 CME / CNE
Global Education Group
The Role of JAK Inhibitors in Closing Gaps in RA Management — Best Practices for Implementing JAK Inhibitors Into RA Management Plans

The Role of JAK Inhibitors in Closing Gaps in RA Management — Best Practices for Implementing JAK Inhibitors Into RA Management Plans

Start

Activity Details

Free CME/CNE
0.50 AMA PRA Category 1 Credit(s)™/
0.50 contact hour(s)
Released: September 24, 2020
Expires: September 24, 2021
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Translate the latest evidence and guidance regarding JAK inhibitor therapies into RA practice

Faculty

Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, Texas


Dr. Stanley B. Cohen is a clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School and is in private practice at Rheumatology Associates in Dallas, Texas. He is Director of the Rheumatology Division at Texas Health Presbyterian Hospital and Co-Medical Director of Metroplex Clinical Research Center, both in Dallas, Texas. Dr. Cohen received his bachelor’s degree in biology from the University of Virginia in Charlottesville and his medical degree from the University of Alabama at Birmingham, School of Medicine. Dr. Cohen completed his fellowship at the St. Paul Medical Center/Southwestern Medical School in Dallas, Texas.

Dr. Cohen received the Howard C. Coggeshall Lifetime Achievement Service Award from the North Texas Arthritis Foundation in 2006 for longtime support of the Foundation and its programs. Author or coauthor of numerous articles and scientific papers and medical books on rheumatic diseases, he lectures on the research and treatment of arthritis and glucocorticoid-induced osteoporosis and serves as advisor to major pharmaceutical companies. He is a past president of the American College of Rheumatology (ACR) and the ACR Rheumatology Research Foundation.

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California


Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.50 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stanley B. Cohen, MD
Grants/Research Support: AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.
Honoraria: Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.50 AMA PRA Category 1 Credit(s)™/
0.50 contact hour(s)
Released: September 24, 2020
Expires: September 24, 2021
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Translate the latest evidence and guidance regarding JAK inhibitor therapies into RA practice

Faculty

Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, Texas


Dr. Stanley B. Cohen is a clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School and is in private practice at Rheumatology Associates in Dallas, Texas. He is Director of the Rheumatology Division at Texas Health Presbyterian Hospital and Co-Medical Director of Metroplex Clinical Research Center, both in Dallas, Texas. Dr. Cohen received his bachelor’s degree in biology from the University of Virginia in Charlottesville and his medical degree from the University of Alabama at Birmingham, School of Medicine. Dr. Cohen completed his fellowship at the St. Paul Medical Center/Southwestern Medical School in Dallas, Texas.

Dr. Cohen received the Howard C. Coggeshall Lifetime Achievement Service Award from the North Texas Arthritis Foundation in 2006 for longtime support of the Foundation and its programs. Author or coauthor of numerous articles and scientific papers and medical books on rheumatic diseases, he lectures on the research and treatment of arthritis and glucocorticoid-induced osteoporosis and serves as advisor to major pharmaceutical companies. He is a past president of the American College of Rheumatology (ACR) and the ACR Rheumatology Research Foundation.

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California


Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.50 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stanley B. Cohen, MD
Grants/Research Support: AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.
Honoraria: Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME / CNE
Global Education Group
The Role of JAK Inhibitors in Closing Gaps in RA Management — Overcoming Access Barriers to RA Treatment: The “How-to”

The Role of JAK Inhibitors in Closing Gaps in RA Management — Overcoming Access Barriers to RA Treatment: The “How-to”

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)™/
0.25 contact hour(s)
Released: September 24, 2020
Expires: September 24, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Employ strategies to assist patients in overcoming access barriers to effective RA therapies

Faculty

Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, Texas


Dr. Stanley B. Cohen is a clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School and is in private practice at Rheumatology Associates in Dallas, Texas. He is Director of the Rheumatology Division at Texas Health Presbyterian Hospital and Co-Medical Director of Metroplex Clinical Research Center, both in Dallas, Texas. Dr. Cohen received his bachelor’s degree in biology from the University of Virginia in Charlottesville and his medical degree from the University of Alabama at Birmingham, School of Medicine. Dr. Cohen completed his fellowship at the St. Paul Medical Center/Southwestern Medical School in Dallas, Texas.

Dr. Cohen received the Howard C. Coggeshall Lifetime Achievement Service Award from the North Texas Arthritis Foundation in 2006 for longtime support of the Foundation and its programs. Author or coauthor of numerous articles and scientific papers and medical books on rheumatic diseases, he lectures on the research and treatment of arthritis and glucocorticoid-induced osteoporosis and serves as advisor to major pharmaceutical companies. He is a past president of the American College of Rheumatology (ACR) and the ACR Rheumatology Research Foundation.

Madelaine A. Feldman, MD, FACR
President, Coalition of State Rheumatology Organizations
Chair, Alliance for Safe Biologic Medicines
Clinical Assistant Professor of Medicine
Tulane University School of Medicine
The Rheumatology Group
New Orleans, Louisiana


Dr. Madelaine Feldman is a rheumatologist in private practice with The Rheumatology Group in New Orleans, Louisiana. She is President of the Coalition of State Rheumatology Organizations, Chair of the Alliance for Safe Biologic Medicines, and past member of the American College of Rheumatology insurance subcommittee.

A Clinical Assistant Professor of Medicine at Tulane University School of Medicine in New Orleans, Louisiana, she has testified before the Energy and Commerce Subcommittee on Health regarding transparency in drug pricing and the drug supply chain (specifically pharmacy benefit managers [PBMs), and several state legislative committees on PBMs and transparency.

Dr. Feldman received the Distinguished Service Award from Tulane Medical School and was named one of the Top Women in New Orleans by City Business in 2017.

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California


Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.25 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stanley B. Cohen, MD
Grants/Research Support: AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.
Honoraria: Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.

Madelaine A. Feldman, MD, FACR
Consultant/Independent Contractor: Bristol Myers Squibb Company, Gilead Sciences, Inc.
Speakers Bureau: Eli Lilly and Company.
Stock Shareholder: Celgene Corporation.

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)™/
0.25 contact hour(s)
Released: September 24, 2020
Expires: September 24, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Employ strategies to assist patients in overcoming access barriers to effective RA therapies

Faculty

Stanley B. Cohen, MD
Clinical Professor, Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, Texas


Dr. Stanley B. Cohen is a clinical professor in the Department of Internal Medicine at the University of Texas Southwestern Medical School and is in private practice at Rheumatology Associates in Dallas, Texas. He is Director of the Rheumatology Division at Texas Health Presbyterian Hospital and Co-Medical Director of Metroplex Clinical Research Center, both in Dallas, Texas. Dr. Cohen received his bachelor’s degree in biology from the University of Virginia in Charlottesville and his medical degree from the University of Alabama at Birmingham, School of Medicine. Dr. Cohen completed his fellowship at the St. Paul Medical Center/Southwestern Medical School in Dallas, Texas.

Dr. Cohen received the Howard C. Coggeshall Lifetime Achievement Service Award from the North Texas Arthritis Foundation in 2006 for longtime support of the Foundation and its programs. Author or coauthor of numerous articles and scientific papers and medical books on rheumatic diseases, he lectures on the research and treatment of arthritis and glucocorticoid-induced osteoporosis and serves as advisor to major pharmaceutical companies. He is a past president of the American College of Rheumatology (ACR) and the ACR Rheumatology Research Foundation.

Madelaine A. Feldman, MD, FACR
President, Coalition of State Rheumatology Organizations
Chair, Alliance for Safe Biologic Medicines
Clinical Assistant Professor of Medicine
Tulane University School of Medicine
The Rheumatology Group
New Orleans, Louisiana


Dr. Madelaine Feldman is a rheumatologist in private practice with The Rheumatology Group in New Orleans, Louisiana. She is President of the Coalition of State Rheumatology Organizations, Chair of the Alliance for Safe Biologic Medicines, and past member of the American College of Rheumatology insurance subcommittee.

A Clinical Assistant Professor of Medicine at Tulane University School of Medicine in New Orleans, Louisiana, she has testified before the Energy and Commerce Subcommittee on Health regarding transparency in drug pricing and the drug supply chain (specifically pharmacy benefit managers [PBMs), and several state legislative committees on PBMs and transparency.

Dr. Feldman received the Distinguished Service Award from Tulane Medical School and was named one of the Top Women in New Orleans by City Business in 2017.

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California


Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.25 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stanley B. Cohen, MD
Grants/Research Support: AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.
Honoraria: Genentech, Inc., Gilead Sciences, Inc., Pfizer Inc.

Madelaine A. Feldman, MD, FACR
Consultant/Independent Contractor: Bristol Myers Squibb Company, Gilead Sciences, Inc.
Speakers Bureau: Eli Lilly and Company.
Stock Shareholder: Celgene Corporation.

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME / CNE
Global Education Group
The Role of JAK Inhibitors in Closing Gaps in RA Management — Class in Session: JAK Inhibitor Facts—From Established Data to Clinical Trial Updates

The Role of JAK Inhibitors in Closing Gaps in RA Management — Class in Session: JAK Inhibitor Facts—From Established Data to Clinical Trial Updates

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)™/
0.25 contact hour(s)
Released: September 24, 2020
Expires: September 24, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Outline the efficacy, safety, selectivity, and clinical trial data of JAK inhibitors

Faculty

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California


Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.25 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)™/
0.25 contact hour(s)
Released: September 24, 2020
Expires: September 24, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Target Audience

The educational design of this activity addresses the needs of rheumatologists, rheumatology specialist nurse practitioners and physician assistants, with the overall goal of improving the care of patients with rheumatoid arthritis (RA).

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Outline the efficacy, safety, selectivity, and clinical trial data of JAK inhibitors

Faculty

Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant
Palo Alto, California


Dr. Vibeke Strand serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years in subspecialty practice in San Francisco, California, and a clinical investigator and senior director of clinical research at 3 pharmaceutical/biotech companies. Adjunct Clinical Professor at Stanford University, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results, and presentation of novel products for approval to the US Food and Drug Administration (FDA) and European Medicines Agency. An invited member of FDA Arthritis Advisory Committee meetings discussing Guidance Documents, she has assisted in preparation of briefing documents, analyses, and data presentation for defense of New Drug and Biologics License Applications in RA and many other rheumatological diseases and the first and subsequent monoclonal antibody biosimilars.

Dr. Strand established and cochaired the biennial “Innovative Therapies in Autoimmune Disease” meetings cosponsored by the American College of Rheumatology (ACR), National Institutes of Health, and FDA. A founding member of the Executive Committee of the international OMERACT [Outcome Measures in Rheumatology] consensus conferences and of GRAPPA [Group for Research and Assessment of Psoriasis], she has served on the ACR RA Clinical Trials Task Force, ACR Board of Directors, Medical and Scientific Committee of the Northern California Chapter of the Arthritis Foundation, Board of Directors of Corrona, and Scientific Advisory Board and Board of Advisors for ACTTION [Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks]. Author of over 400 original publications, she is a Fellow of the American College of Physicians, Master of the American College of Rheumatology, and member of the Cosmos Club and its Substitute Board of Managers.

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications.  Global is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.25 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on September 24, 2020 and is valid for 1 year. Requests for credit must be made no later than September 24, 2021.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the learning objectives, complete the pretest, review the activity, score 100% on the posttest, and complete the evaluation form.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Vibeke Strand, MD, MACR, FACR
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Asana BioSciences LLC, AstraZeneca plc, Bayer AG, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Celgene Corporation, Celltrion Healthcare Co., Ltd., Corrona, LLC, Crescendo Bioscience, Inc./Myriad Genetics, Inc., EMD Serono, Inc., Eupraxia Pharmaceuticals Inc., Flexion Therapeutics Inc., Genentech Inc./Roche, GlaxoSmithKline, Horizon Therapeutics plc, Inmedix, Inc., Janssen Pharmaceuticals, Inc., Kezar Life Sciences, Inc., Kypha Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Royalty Pharma, RRD International, Samsung Biologics, Samumed, LLC., Sandoz Inc., sanofi-aventis U.S. LLC, Selecta Biosciences, Inc., Servier Laboratories, SetPoint Medical Corporation, SKK, UCB S.A.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Celeste Collazo, MD - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.75 CME
Integrity Continuing Education, Inc.
Why Weight? The Family Practice Guide for Enhancing the Patient-Provider Connection in Obesity Management

Why Weight? The Family Practice Guide for Enhancing the Patient-Provider Connection in Obesity Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 31, 2020
Expires: July 31, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion​
  • Examine regional and ethnic disparities to tailor obesity interventions appropriately​
  • Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment​
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance

Activity Description

Obesity rates are increasing, and contrary to other major global risks, there is little evidence of successful population-level intervention strategies to reduce rates. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of clinicians. It is well known that there is a growing shortage of obesity specialists in the United States who diagnose and manage interrelated cardiometabolic diseases. Therefore, family practice physicians are expected to become the frontline providers to manage obesity in the near future.

A comprehensive, patient-centered approach to obesity improves patient outcomes, but rarely is implemented. In order for a patient-centered approach to be implemented, clinicians are required to know how to effectively engage their patients and be up-to-date on current medical anti-obesity therapies so they can select the most appropriate agent for their individual patient’s needs. This innovative activity will incorporate multiple evidence-based adult learning principles to improve family physicians' skills and confidence in weight-loss counseling and treatment.

Faculty

Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Gelesis, Medtronic, Novo Nordisk
Speakers’ BureausNovo Nordisk
Contracted Research: Novo Nordisk 

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2020 through July 31, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk, Inc.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 31, 2020
Expires: July 31, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion​
  • Examine regional and ethnic disparities to tailor obesity interventions appropriately​
  • Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment​
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance

Activity Description

Obesity rates are increasing, and contrary to other major global risks, there is little evidence of successful population-level intervention strategies to reduce rates. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of clinicians. It is well known that there is a growing shortage of obesity specialists in the United States who diagnose and manage interrelated cardiometabolic diseases. Therefore, family practice physicians are expected to become the frontline providers to manage obesity in the near future.

A comprehensive, patient-centered approach to obesity improves patient outcomes, but rarely is implemented. In order for a patient-centered approach to be implemented, clinicians are required to know how to effectively engage their patients and be up-to-date on current medical anti-obesity therapies so they can select the most appropriate agent for their individual patient’s needs. This innovative activity will incorporate multiple evidence-based adult learning principles to improve family physicians' skills and confidence in weight-loss counseling and treatment.

Faculty

Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Gelesis, Medtronic, Novo Nordisk
Speakers’ BureausNovo Nordisk
Contracted Research: Novo Nordisk 

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2020 through July 31, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk, Inc.

1.00 CME
Academy for Continued Healthcare Learning
Revolutionizing T2T in RA: Future Paradigms with JAK Inhibitors

Revolutionizing T2T in RA: Future Paradigms with JAK Inhibitors

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 24, 2020
Expires: July 24, 2021
60 minutes to complete

Accredited By

Target Audience

This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
  • Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
  • Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors

Activity Description

How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.

Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.

Bonus supplemental material includes:

  • Understanding Discordance in RA Care
  • Patient Perspectives on Shared Decision-Making
  • What Patients with RA Want Their Rheumatologists to Know
  • EULAR 2020 RA Updates

Statement of Educational Need

Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.

As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.

Agenda

Clinical commentary highlights includes:

  • Available and emerging JAK inhibitors
  • Tactics for patients who may have a poor response to biologic treatment
  • Role and adverse event management of small molecule drugs 
  • The latest treat-to-target paradigms

Chair

Kevin Winthrop, MD, MPH
Professor,
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR


Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA


William F.C. Rigby, MD
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH


Patient Ambassadors

Kelly O'Neill
Founder, Rheumatoid Arthritis Warrior Community
RAwarrior.com
Founder, Rheumatoid Patient Foundation


Shannon Young, EdD
Executive Director,
Rheumatoid Patient Foundation
rheum4us.org


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB

Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen, Lilly, Novartis, Pfizer Inc., UCB

William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under investigation for RA

Patient Ambassador Disclosures

Kelly O'Neill and Shannon Young, EdD, have no financial relationships.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org 

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 24, 2020
Expires: July 24, 2021
60 minutes to complete

Accredited By

Target Audience

This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
  • Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
  • Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors

Activity Description

How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.

Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.

Bonus supplemental material includes:

  • Understanding Discordance in RA Care
  • Patient Perspectives on Shared Decision-Making
  • What Patients with RA Want Their Rheumatologists to Know
  • EULAR 2020 RA Updates

Statement of Educational Need

Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.

As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.

Agenda

Clinical commentary highlights includes:

  • Available and emerging JAK inhibitors
  • Tactics for patients who may have a poor response to biologic treatment
  • Role and adverse event management of small molecule drugs 
  • The latest treat-to-target paradigms

Chair

Kevin Winthrop, MD, MPH
Professor,
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR


Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA


William F.C. Rigby, MD
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH


Patient Ambassadors

Kelly O'Neill
Founder, Rheumatoid Arthritis Warrior Community
RAwarrior.com
Founder, Rheumatoid Patient Foundation


Shannon Young, EdD
Executive Director,
Rheumatoid Patient Foundation
rheum4us.org


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB

Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen, Lilly, Novartis, Pfizer Inc., UCB

William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under investigation for RA

Patient Ambassador Disclosures

Kelly O'Neill and Shannon Young, EdD, have no financial relationships.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org 

0.25 CME / MOC
The France Foundation
Integrative Solutions to Challenges in Chronic Pain Management – Patient Case: Osteoarthritis (OA) of the Knee

Integrative Solutions to Challenges in Chronic Pain Management – Patient Case: Osteoarthritis (OA) of the Knee

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Released: July 22, 2020
Expires: July 21, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

  • Describe recent developments in the understanding of pain pathways/pain pathophysiology
  • Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
  • Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
  • Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

STEERING COMMITTEE
Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
  • Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.


Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
  • Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.


Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
  • Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

  • Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
    • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Released: July 22, 2020
Expires: July 21, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

  • Describe recent developments in the understanding of pain pathways/pain pathophysiology
  • Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
  • Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
  • Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

STEERING COMMITTEE
Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
  • Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.


Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
  • Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.


Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
  • Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

  • Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
    • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.25 CME / MOC
The France Foundation
Integrative Solutions to Challenges in Chronic Pain Management – Applying Principles of Pain Management

Integrative Solutions to Challenges in Chronic Pain Management – Applying Principles of Pain Management

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Released: July 22, 2020
Expires: July 21, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

  • Describe recent developments in the understanding of pain pathways/pain pathophysiology
  • Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
  • Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
  • Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

STEERING COMMITTEE
Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
  • Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.


Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
  • Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.


Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
  • Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

  • Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
    • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Released: July 22, 2020
Expires: July 21, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

  • Describe recent developments in the understanding of pain pathways/pain pathophysiology
  • Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
  • Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
  • Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

STEERING COMMITTEE
Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
  • Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.


Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
  • Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.


Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
  • Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

  • Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
    • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.75 CME
Integrity Continuing Education, Inc.
Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.25 CME
Medical Education Resources (MER)
Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Exploring the Advantages of Early Treatment for Diabetic Eye Disease

Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Exploring the Advantages of Early Treatment for Diabetic Eye Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 15, 2020
Expires: July 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™, Medical Education Resources, and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Strategies for improved patient care
  • Differences between proliferative diabetic retinopathy (PDR) and nonproliferative diabetic retinopathy (NPDR)
  • Evolution of the nonproliferative diabetic retinopathy classifications systems
  • Progression of nonproliferative diabetic retinopathy to sight-threatening DR and blindness
  • Potential benefits of treating patients who have NPDR

Faculty

Rishi P. Singh, MD
Staff Surgeon
Cole Eye Institute
Cleveland Clinic
Associate Professor of Ophthalmology
Lerner College of Medicine
Cleveland, OH


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funded by Apellis and Graybug. Additionally, he has received consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 15, 2020
Expires: July 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™, Medical Education Resources, and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Strategies for improved patient care
  • Differences between proliferative diabetic retinopathy (PDR) and nonproliferative diabetic retinopathy (NPDR)
  • Evolution of the nonproliferative diabetic retinopathy classifications systems
  • Progression of nonproliferative diabetic retinopathy to sight-threatening DR and blindness
  • Potential benefits of treating patients who have NPDR

Faculty

Rishi P. Singh, MD
Staff Surgeon
Cole Eye Institute
Cleveland Clinic
Associate Professor of Ophthalmology
Lerner College of Medicine
Cleveland, OH


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funded by Apellis and Graybug. Additionally, he has received consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Pages